Pancreatic cancer often spreads, forming metastases in the liver or lungs. The prognosis is better for patients with metastases in the lungs. However, the organ that is more likely to be affected depends on the cancer cells' ability to alter their characteristics and shape - as a research team at the Technical University of Munich (TUM) has discovered
Studying two rare inherited cancer syndromes, scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery suggests a promising strategy for treatment with drugs recently approved for other forms of cancer, said the researchers.
MicroRNAs are small non-coding pieces of genetic material that are involved in the regulation of gene expression. The research team found two microRNA activity-based biomarkers that can help indicate which patients may have a better rather than worse patient prognosis.
John Ryan is just one of the miracles to emerge from the Johns Hopkins cancer unit in Baltimore. An immunotherapy treatment — highly effective in a minority of patients — saved his life after a lung cancer diagnosis.
Cancer researchers have shown that some patients with T-cell leukaemia produce too much of the BCL-2 protein. Cancer cells take advantage of this ‘survival protein’ which allows them to escape chemotherapy. A drug suppressing this BCL-2 shows promising results.
Although immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no any immunotherapeutic strategy for breast cancer (BC). Thus, it is important to discover biomarkers for identifying the BC patients responsive to immunotherapy.